These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1058 related items for PubMed ID: 34991494

  • 1. Roles of extended human papillomavirus genotyping and multiple infections in early detection of cervical precancer and cancer and HPV vaccination.
    Song F, Yan P, Huang X, Wang C, Du H, Qu X, Wu R.
    BMC Cancer; 2022 Jan 06; 22(1):42. PubMed ID: 34991494
    [Abstract] [Full Text] [Related]

  • 2. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
    Arbyn M, Xu L, Simoens C, Martin-Hirsch PP.
    Cochrane Database Syst Rev; 2018 May 09; 5(5):CD009069. PubMed ID: 29740819
    [Abstract] [Full Text] [Related]

  • 3. Fraction of high-grade cervical intraepithelial lesions attributable to genotypes targeted by a nonavalent HPV vaccine in Galicia, Spain.
    Perez S, Iñarrea A, Pérez-Tanoira R, Gil M, López-Díez E, Valenzuela O, Porto M, Alberte-Lista L, Peteiro-Cancelo MA, Treinta A, Carballo R, Reboredo MC, Alvarez-Argüelles ME, Purriños MJ.
    Virol J; 2017 Nov 06; 14(1):214. PubMed ID: 29110680
    [Abstract] [Full Text] [Related]

  • 4. The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States.
    Wheeler CM, Hunt WC, Cuzick J, Langsfeld E, Robertson M, Castle PE, New Mexico HPV Pap Registry Steering Committee.
    Int J Cancer; 2014 Aug 01; 135(3):624-34. PubMed ID: 24226935
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Performance of HPV Genotyping Combined with p16/Ki-67 in Detection of Cervical Precancer and Cancer Among HPV-Positive Chinese Women.
    Jiang MY, Wu Z, Li T, Yu L, Zhang SK, Zhang X, Qu P, Sun P, Xi MR, Liu X, Liao G, Sun L, Zhang Y, Chen W, Qiao YL.
    Cancer Prev Res (Phila); 2020 Feb 01; 13(2):163-172. PubMed ID: 31871224
    [Abstract] [Full Text] [Related]

  • 7. Triaging HPV-positive, cytology-negative cervical cancer screening results with extended HPV genotyping and p16INK4a immunostaining in China.
    Song F, Yan P, Huang X, Wang C, Qu X, Du H, Wu R.
    BMC Infect Dis; 2021 Apr 30; 21(1):400. PubMed ID: 33931022
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J.
    Health Technol Assess; 2014 Apr 30; 18(23):1-196. PubMed ID: 24762804
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. High-risk human papillomavirus genotype distribution and attribution to cervical cancer and precancerous lesions in a rural Chinese population.
    Zhao XL, Hu SY, Zhang Q, Dong L, Feng RM, Han R, Zhao FH.
    J Gynecol Oncol; 2017 Jul 30; 28(4):e30. PubMed ID: 28541628
    [Abstract] [Full Text] [Related]

  • 13. Estimating the direct effect of human papillomavirus vaccination on the lifetime risk of screen-detected cervical precancer.
    Inturrisi F, Lissenberg-Witte BI, Veldhuijzen NJ, Bogaards JA, Ronco G, Meijer CJLM, Berkhof J.
    Int J Cancer; 2021 Jan 15; 148(2):320-328. PubMed ID: 32663316
    [Abstract] [Full Text] [Related]

  • 14. Trends in Human Papillomavirus Vaccine Types 16 and 18 in Cervical Precancers, 2008-2014.
    McClung NM, Gargano JW, Bennett NM, Niccolai LM, Abdullah N, Griffin MR, Park IU, Cleveland AA, Querec TD, Unger ER, Markowitz LE, HPV-IMPACT Working Group.
    Cancer Epidemiol Biomarkers Prev; 2019 Mar 15; 28(3):602-609. PubMed ID: 30792242
    [Abstract] [Full Text] [Related]

  • 15. Clinical evaluation of primary human papillomavirus (HPV) testing with extended HPV genotyping triage for cervical cancer screening: A pooled analysis of individual patient data from nine population-based cervical cancer screening studies from China.
    Dun C, Yuan M, Zhao X, Hu S, Arbyn M, Zhao F.
    Cancer Med; 2024 Jun 15; 13(11):e7316. PubMed ID: 38828559
    [Abstract] [Full Text] [Related]

  • 16. Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study.
    Egli-Gany D, Spaar Zographos A, Diebold J, Masserey Spicher V, Frey Tirri B, Heusser R, Dillner J, Petignat P, Sahli R, Low N, CIN3+plus study group.
    BMC Cancer; 2019 Jan 30; 19(1):111. PubMed ID: 30700274
    [Abstract] [Full Text] [Related]

  • 17. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.
    Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M.
    J Natl Cancer Inst; 2005 Jul 20; 97(14):1072-9. PubMed ID: 16030305
    [Abstract] [Full Text] [Related]

  • 18. Identification of HPV genotypes causing cervical precancer using tissue-based genotyping.
    Venetianer R, Clarke MA, van der Marel J, Tota J, Schiffman M, Dunn ST, Walker J, Zuna R, Quint W, Wentzensen N.
    Int J Cancer; 2020 May 15; 146(10):2836-2844. PubMed ID: 32037535
    [Abstract] [Full Text] [Related]

  • 19. [Risk stratification of type-specific human papillomavirus for cervical precancers: evidence from a cross-sectional study in Shenzhen].
    Liu ZH, Lin W, Wang YY, Wu B, Yuan SX, Yao JL, Zhao XS, Chen B, Qiao YL, Zhao FH, Chen W, Hu SY.
    Zhonghua Zhong Liu Za Zhi; 2018 Oct 23; 40(10):757-763. PubMed ID: 30392340
    [Abstract] [Full Text] [Related]

  • 20. Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial.
    Shing JZ, Hu S, Herrero R, Hildesheim A, Porras C, Sampson JN, Schussler J, Schiller JT, Lowy DR, Sierra MS, Carvajal L, Kreimer AR, Costa Rica HPV Vaccine Trial Group.
    Lancet Oncol; 2022 Jul 23; 23(7):940-949. PubMed ID: 35709811
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.